相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s
Joshua Kellner et al.
JCI INSIGHT (2019)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall et al.
JCI INSIGHT (2018)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yinmeng Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu
L. Zhang et al.
BLOOD CANCER JOURNAL (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression
Achilleas Floudas et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells
Aharon Kessel et al.
AUTOIMMUNITY REVIEWS (2012)
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
Hiroki Torikai et al.
BLOOD (2012)
Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher et al.
CLINICAL CANCER RESEARCH (2012)
Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
Alice P. Chen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
N. Hosen et al.
LEUKEMIA (2012)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
分享论文
